Mark Cuban discusses his approach to fixing healthcare, emphasizing transparency in drug pricing and the need to dismantle the influence of pharmacy benefit managers. He advocates for cash pricing legislation and supports the Break Up Big Medicine Act to separate insurance companies from their non-insurance interests.

• The Dallas Mavericks paid $169,000 for generic drugs that would have cost just $19,000 through Cuban's Cost Plus company.
• Cuban backs the Break Up Big Medicine Act, which would force insurance companies to divest their PBM arms.
• He wants legislation requiring cash drug payments to count toward insurance deductibles, plus state-controlled formularies to curb PBM power.
• He gave TrumpRx an "A-" and says FDA application costs, not tariffs, are the real barrier to bringing generic manufacturing to the US.

Mark Cuban and Optum CEO Patrick Conway engaged in a heated discussion about drug prices and pharmacy benefit managers, highlighting their differing views on how to reform the healthcare system. Cuban argued for breaking up large insurance companies and criticized the lack of transparency in PBM contracts, while Conway emphasized the need to tackle high hospital and pharmaceutical costs. Both acknowledged the other's contributions but remained divided on the root causes of high drug prices and solutions.

• Cuban challenged Conway to name a specific Optum customer he could call to verify claims about PBM contract transparency
• Cuban advocates breaking up large insurance companies as a fix, blaming opaque PBM contracts for inflated drug prices
• Conway countered that high hospital and pharmaceutical costs, not just PBMs, are the core drivers of the problem
• Despite the confrontational exchange, both men acknowledged each other's contributions while disagreeing on root causes and solutions